TW200722092A - Low dose administration of a topical composition - Google Patents

Low dose administration of a topical composition

Info

Publication number
TW200722092A
TW200722092A TW095116143A TW95116143A TW200722092A TW 200722092 A TW200722092 A TW 200722092A TW 095116143 A TW095116143 A TW 095116143A TW 95116143 A TW95116143 A TW 95116143A TW 200722092 A TW200722092 A TW 200722092A
Authority
TW
Taiwan
Prior art keywords
low dose
topical composition
dose administration
individual
active ingredient
Prior art date
Application number
TW095116143A
Other languages
Chinese (zh)
Inventor
Thomas Chan
Original Assignee
Macrochem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrochem Corp filed Critical Macrochem Corp
Publication of TW200722092A publication Critical patent/TW200722092A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Unexpectedly, the therapeutically required amount of active ingredient in a topical drug delivery product may be significantly reduced by applying the product in a delivery vehicle containing a SEPA ® penetration enhancer to the upper arms and shoulders of an individual in need of the active ingredient rather than to the abdomen of the individual.
TW095116143A 2005-05-11 2006-05-05 Low dose administration of a topical composition TW200722092A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67967305P 2005-05-11 2005-05-11

Publications (1)

Publication Number Publication Date
TW200722092A true TW200722092A (en) 2007-06-16

Family

ID=37431780

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095116143A TW200722092A (en) 2005-05-11 2006-05-05 Low dose administration of a topical composition

Country Status (7)

Country Link
EP (1) EP1879593A2 (en)
JP (1) JP2009504566A (en)
AU (1) AU2006247934A1 (en)
CA (1) CA2608189A1 (en)
MX (1) MX2007013912A (en)
TW (1) TW200722092A (en)
WO (1) WO2006124275A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6863832B2 (en) * 2016-07-21 2021-04-21 日清ファルマ株式会社 Composition for suppressing muscle atrophy
US20230041289A1 (en) * 2021-08-05 2023-02-09 Innovus Pharmaceuticals, Inc. Compositions and methods for enhancing or treating female sexual response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861764A (en) * 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
US5849729A (en) * 1995-12-26 1998-12-15 Hershey Foods Corporation Use of hydrolyzed cocoa butter for percutaneous absorption

Also Published As

Publication number Publication date
WO2006124275A2 (en) 2006-11-23
EP1879593A2 (en) 2008-01-23
WO2006124275A3 (en) 2009-04-09
AU2006247934A1 (en) 2006-11-23
CA2608189A1 (en) 2006-11-23
MX2007013912A (en) 2008-03-25
JP2009504566A (en) 2009-02-05

Similar Documents

Publication Publication Date Title
WO2008027854A3 (en) Pharmaceutical compositions comprising hgh for oral delivery
WO2006082588A3 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
UA88464C2 (en) Method of topical methadone administration providing systemic effect
EP2246049A3 (en) Pharmaceutical composition and dosage forms for administration of hydrophobic drugs
WO2008070149A3 (en) Prodrugs and methods of making and using the same
WO2008027350A3 (en) Acetaminophen pharmaceutical compositions
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
MXPA06012960A (en) Transdermal administration of phycotoxins.
HK1123213A1 (en) Reduction of dizziness, a side effect associated with pirfenidone therapy
WO2008023016A3 (en) Galenic formulations of aliskiren
HK1176318A1 (en) Injection device
CA3010829A1 (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
WO2011159100A2 (en) Anti-cancer pharmaceutical composition
EP2316420A8 (en) Method to reduce pain
WO2008116004A3 (en) Transdermal patch and method for delivery of vitamin b12
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
IL179177A (en) Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2004112838A3 (en) Codrugs of diclofenac
TW200722092A (en) Low dose administration of a topical composition
EP3978027A4 (en) Physiologically active substance bound to biotin moiety, and composition for oral administration including same
WO2008041116A3 (en) Formulations of active principles incorporated in slns suitable for transdermal administration
JO2492B1 (en) pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
WO2008065144A3 (en) Galenic formulations of organic compounds